HHSN272201600029C

IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

National Institutes of Health · United States

This contract has been awarded. Browse open opportunities

View Source

Time Left to Bid

Awarded

AwardedHealthcare & MedicalFederal

Basic information

Reference number: HHSN272201600029C
Issuing organization: National Institutes of Health · Find award history →
Government level: Federal
Solicitation type: Healthcare & Medical
Title: IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.
Source: USASpending (Federal)
Source ID: usa-HHSN272201600029C

Details

Location: United States

Description

IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. Awarded to: VENATORX PHARMACEUTICALS INC Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT

Dates

Publication: 2016/09/19 12:00:00 AM UTC
Closing date: 2026/03/31 12:00:00 AM UTC

Estimated value

$48.5M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-09-02, 12:09:57 p.m.

Data refreshed every 2 hours